Capsid-incorporation of HIV antigens as a novel adenovirus HIV vaccine approach

HIV 抗原衣壳掺入作为新型腺病毒 HIV 疫苗方法

• 批准号: 8124035
• 负责人: David Terry Curiel
• 金额: $ 1.84万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8124035
• 关键词: Achievement; Adenovirus Vector; Adenovirus hexon capsid protein; Adenoviruses; Animal Model; Animal Welfare; Antigens; Bibliography; Biological; Biological Models; Capsid; Capsid Proteins; Cavia; Cells; Clinical Trials; Country; Cryoelectron Microscopy; Data; Effectiveness; Environment; Environmental Impact; Epitopes; Equipment; Gene Delivery; Genes; Genetic Transduction; Genome; Goals; HIV; HIV Antigens; HIV immunization; HIV vaccine; Human; Humoral Immunities; IACUC; Immune response; Immunization; International; Intervention; Locales; Methods; Modeling; Names; Pathway interactions; Peptides; Principal Investigator; Process; Proteins; Pseudomonas; Recombinants; Research; Research Ethics Committees; Resolution; Resources; Severe Acute Respiratory Syndrome; Structure; Surface; Technology; Transgenes; Vaccination; Vaccines; Vertebrates; Viral Vector; Virion; abstracting; base; design; expiration; human subject; immunogenic; in vitro Assay; novel; particle; programs; reconstruction; response; vaccine efficacy; vector; vector vaccine

Principal Investigator/Program Director (Last, first, middle): Curiel, David, T. RESEARCH & RELATED Other Project Information 1. * Are Human Subjects Involved? m Yes l No 1.a. If YES to Human Subjects Is the IRB review Pending? m Yes m No IRB Approval Date: Exemption Number: 1 2 3 4 5 6 Human Subject Assurance Number 2. * Are Vertebrate Animals Used? l Yes m No 2.a. If YES to Vertebrate Animals Is the IACUC review Pending? l Yes m No IACUC Approval Date: Animal Welfare Assurance Number A3255-01 3. * Is proprietary/privileged information m Yes l No included in the application? 4.a.* Does this project have an actual or potential impact on m Yes l No the environment? 4.b. If yes, please explain: 4.c. If this project has an actual or potential impact on the environment, has an exemption been authorized or an environmental assessment (EA) or environmental impact statement (EIS) been performed? m Yes m No 4.d. If yes, please explain: 5.a.* Does this project involve activities outside the U.S. or m Yes l No partnership with International Collaborators? 5.b. If yes, identify countries: 5.c. Optional Explanation: 6. * Project Summary/Abstract 1235-Project__Summary__Curiel.pdf Mime Type: application/pdf 7. * Project Narrative 4856-Project__Narrative_Curiel.pdf Mime Type: application/pdf 8. Bibliography & References Cited 3112-Reference_List_Curiel.pdf Mime Type: application/pdf 9. Facilities & Other Resources 2477-FACILITIES.pdf Mime Type: application/pdf 10. Equipment 1015-EQUIPMENT.pdf Mime Type: application/pdf Tracking Number: Other Information Page 5 OMB Number: 4040-0001 Expiration Date: 04/30/2008 Principal Investigator/Program Director (Last, first, middle): Curiel, David, T. Despite the many potential advantages of Ad vectors for vaccine application, full utility of current Ad vaccines may be limited by the host anti-vector immune response. Specifically, the anti-Ad humoral immunity abrogates the effectiveness of subsequent administrations of the Ad vector, confounding expression of the encoded transgene, and thus practically restricting the gains that might be accrued via booster effect. In order to exploit the inherent antigenicity of the Ad vector we have developed a vaccination approach based on incorporation of the immunizing antigen epitope directly into the Ad capsid. This novel paradigm is based upon Ad presenting the antigen as a component of the capsid rather than an encoded transgene. Incorporation of immunogenic peptides into the Ad capsid offers potential advantages. Most noteworthy, the processing of the capsid incorporated antigen via the exogenous pathway should result in a strong humoral response akin to the response provoked by native Ad capsid proteins. In addition, since anti-Ad capsid responses are augmented by repeated vector administration, immune responses against antigenic epitopes that are part of the Ad capsid should be augmented by repeated administration as well, thus allowing boosting. These considerations suggest that this novel capsid-incorporated antigen approach may offer exciting potentials to realize Ad-based vaccine strategies that circumvent the major limitations associated with Ad vectors. Critical to the realization of this approach is to define the optimal configuration of antigen in the adenoviral capsid context. To this end, we have established several key technologies that will enable us to reach our goal. In particular, we have developed the means to incorporate heterologous peptide epitopes within the surface-exposed domains of the major Ad capsid protein hexon. We have begun to determine the size and structural factors that predicate functional utility of these domains in the hexon. In addition, we have developed the means to apply cryoelectron microscopy (cryoEM) single particle reconstruction methods to allow us to explore the capsid-incorporated peptide localization with unprecedented, subnanometer resolution. Based on these technologies, we will be able to establish the critical correlates between antigen locale/accessibility within the capsid context and vaccine efficacy. On the basis of these established feasibilities, we hypothesize that Ad vectors can be created with novel capsid-incorporated antigens that can serve as vaccine agents against HIV in animal models. CryoEM-guided capsid design will be applied to develop an optimized vector with optimal anti-HIV immunization. We envision that our proposed structural studies will provide complementary information to in vitro assays and biological readouts and thereby will enable us to understand the functional determinants of incorporated HIV epitopes. Project Description Page 6

首席研究员/项目总监（后、一、中）：Curiel, David， T。